nejm retatrutide 📊 Semaglutide 2.4mg: −13.7% weight loss (SURMOUNT-5 head-to-head), 📊 Tirzepatide 15mg: −20.2% weight loss (same trial, 2025), 📊 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Retatrutide 10mg & 20mg Research

That approval came after two pivotal Phase 3 trials involving more than 800 participants, where Tesamorelin demonstrated reductions in visceral adipose tissue (VAT) of 15 to 20% over 26 weeks

Constipation affects approximately 21% of people taking Retatrutide at the 12mg dose, making it the third most common side effect after nausea and diarrhea

In adults with obesity, a weekly 2.4 mg dose led to about 15% body weight lost over 68 weeks

The Issue of Weight Regain Research indicates that approximately 76% of individuals regain their lost weight after discontinuing GLP-1 injections, typically within two years

Weight loss treatment made easy

But VIBES works similarly to another device, Moran says